A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.
EP. 1: Phase 2 L-MIND Trial Overview
EP. 2: RE-MIND Comparison Data Review
EP. 3: L-MIND and RE-MIND Practical Implications
2 Clarke Drive Cranbury, NJ 08512